Brokers Offer Predictions for ARWR Q2 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Investment analysts at B. Riley issued their Q2 2025 earnings per share (EPS) estimates for shares of Arrowhead Pharmaceuticals in a note issued to investors on Thursday, December 12th. B. Riley analyst M. Mamtani expects that the biotechnology company will earn ($0.62) per share for the quarter. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.72) per share. B. Riley also issued estimates for Arrowhead Pharmaceuticals’ Q4 2025 earnings at ($1.02) EPS.

Several other analysts also recently issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arrowhead Pharmaceuticals in a report on Monday, September 9th. HC Wainwright upped their price target on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a report on Tuesday, December 3rd. Citigroup dropped their price objective on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 27th. StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a research note on Wednesday, November 27th. Finally, Piper Sandler dropped their price target on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 27th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $42.70.

Arrowhead Pharmaceuticals Stock Down 0.4 %

Shares of Arrowhead Pharmaceuticals stock opened at $22.27 on Monday. Arrowhead Pharmaceuticals has a 12-month low of $17.05 and a 12-month high of $39.83. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 2.06. The stock has a 50 day moving average price of $21.06 and a two-hundred day moving average price of $23.14. The stock has a market capitalization of $2.77 billion, a P/E ratio of -4.44 and a beta of 0.91.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of ARWR. Avoro Capital Advisors LLC raised its holdings in shares of Arrowhead Pharmaceuticals by 3.9% in the 2nd quarter. Avoro Capital Advisors LLC now owns 8,888,888 shares of the biotechnology company’s stock worth $231,022,000 after buying an additional 333,333 shares in the last quarter. State Street Corp raised its stake in Arrowhead Pharmaceuticals by 8.8% during the third quarter. State Street Corp now owns 6,354,331 shares of the biotechnology company’s stock worth $123,083,000 after acquiring an additional 516,569 shares in the last quarter. Geode Capital Management LLC raised its stake in Arrowhead Pharmaceuticals by 0.9% during the third quarter. Geode Capital Management LLC now owns 2,964,119 shares of the biotechnology company’s stock worth $57,426,000 after acquiring an additional 26,171 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Arrowhead Pharmaceuticals by 2.9% during the second quarter. Bank of New York Mellon Corp now owns 1,085,069 shares of the biotechnology company’s stock valued at $28,201,000 after acquiring an additional 30,086 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Arrowhead Pharmaceuticals by 1.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,006,935 shares of the biotechnology company’s stock valued at $19,504,000 after purchasing an additional 12,574 shares in the last quarter. Institutional investors own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.